Please ensure Javascript is enabled for purposes of website accessibility Horizon Biotechnology Fund - Janus Henderson Investors
For investors in Singapore

Horizon Biotechnology Fund

ISIN
LU1897414303

NAV
USD 26.86
As of 2024/10/04

1-Day Change
USD -0.14 (-0.52%)
As of 2024/10/04

Morningstar Rating

As of 2024/08/31

Overview

INVESTMENT OBJECTIVE

The Fund aims to provide capital growth over the long term.

More

The Fund invests at least 80% of its assets in shares (equities) and equity-related securities of companies, which are biotechnology or biotechnology-related, in any country.

Less

Note: You should not make investment decisions based solely on marketing materials. You should read the Prospectus and the Product Highlights Sheet of the Fund for more details of the investment risks and seek independent professional advice where appropriate.

ABOUT THIS FUND

  • Invests globally in companies strategically aligned with environmental and social megatrends: climate change, resource constraints, growing populations, and ageing populations
  • Avoids investing in fossil fuels and companies that stand to be disrupted by the transition to a low-carbon economy
  • Experienced team of global equity investors employing a long-term approach and disciplined fundamental analysis

Portfolio Management

Andy Acker, CFA

Portfolio Manager

Industry since 1996. Joined Firm in 1999.

Daniel Lyons, Ph.D., CFA

Portfolio Manager | Research Analyst

Industry since 2000. Joined Firm in 2000.

Agustin Mohedas, Ph.D.

Portfolio Manager | Research Analyst

Industry since 2014.

Performance

Cumulative & Annualised Performance (%)
As of 2024/08/31
A2 USD (With Sales Charge)* NASDAQ Biotechnology Total Return Sector Equity Biotechnology - OE A2 USD (Net)
 
  Cumulative Annualised
1MO 3MO 6MO YTD 1YR 3YR 5YR 10YR Since Inception
2018/12/10
A2 USD (With Sales Charge)* -3.76 6.88 4.24 14.20 25.22 7.72 19.83 - 18.02
NASDAQ Biotechnology Total Return 0.89 11.14 10.71 12.32 19.62 -2.18 9.39 - 8.03
Sector Equity Biotechnology - OE 1.27 9.91 2.30 6.49 14.47 -6.33 4.81 - 4.32
A2 USD (Net) 1.30 12.50 9.73 20.21 31.81 9.57 21.06 - 19.08
Fee Information
Initial Charge 5.00%
Annual Charge 1.20%
Ongoing Charge
(As of 2023/06/30)
1.89%
Performance Fee 20% of the 'Relevant Amount'
Hurdle Rate NASDAQ Biotechnology Total Return Index

Portfolio

Documents